Savient Pharmaceuticals (SVNT) Posts Q4 Loss of 44c/Sh., Misses Views
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/8/2026
- S&P 500, Nasdaq end lower as crude prices jump, chip stocks weigh
- Oil rises 4% on revived Middle East worries, Hurricane Isaias supply disruption
- Chipotle, Starbucks shares volatile after report of potential takeover
- Why Citi says the Fed could be setting up for a dovish surprise
- Alphabet shares rise as Google pushes Gemini deeper into enterprise AI
Tweet
Share
E-mailGet Alerts SVNT Hot Sheet
Join SI Premium – FREE
Savient Pharmaceuticals (NASDAQ: SVNT) reported Q4 EPS of ($0.44), $0.06 worse than the analyst estimate of ($0.38). Revenue for the quarter came in at $3.71 million versus the consensus estimate of $3.51 million.
For earnings history and earnings-related data on Savient Pharmaceuticals (SVNT) click here.
For earnings history and earnings-related data on Savient Pharmaceuticals (SVNT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Potential Starbucks-Chipotle merger: major opportunity or expensive distraction?
- Piper Sandler, KeyBanc bullish on Generac’s expanding data center pipeline
- Sony credit outlook bumped to positive at Moody’s as A2 rating affirmed
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
